NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Bambusa Therapeutics BBTX

Bambusa Therapeutics listed on Nasdaq on 30 Oct 2026 and is not in the S&P 500. Its board is not in our data yet.

Listed
30 Oct 2026 on Nasdaq, IPO filings and terms
Headquarters
Boston, MA

Board and leadership

Board and officers

Bambusa Therapeutics' board is not in our data yet. It listed on 30 Oct 2026 and has not filed a proxy statement. See its 8-K filings.

Owners and trading

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $52.6 million in 3 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
2 Nov 2026BuyPeter KolchinskyDirectorDirectorBuy2,500,000$40M
2 Nov 2026BuyHelmut Wolfgang JeggleDirectorDirectorBuy375,000$6.0M
30 Oct 2026BuyPeter KolchinskyDirectorDirectorBuy453,820$6.6M

Not on file: no weekly market cap history, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months, no quarterly results in its SEC XBRL filings and no director or officer changes, WARN notices or large insider sales in the last two years. 13F holdings: Bambusa Therapeutics listed after the last quarter (30 Jun 2026). The next 13F filings were due by 14 Nov 2026.